{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:32:36Z","timestamp":1773297156476,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"21-22","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.vaccine.2003.12.028","type":"journal-article","created":{"date-parts":[[2004,2,21]],"date-time":"2004-02-21T05:23:30Z","timestamp":1077341010000},"page":"2904-2909","source":"Crossref","is-referenced-by-count":30,"title":["A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside"],"prefix":"10.1016","volume":"22","author":[{"given":"Paul B","family":"Chapman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Salibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jen","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E","family":"Krown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip O","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2003.12.028_BIB1","first-page":"S155","article-title":"Anti-melanoma effects of R24, a monoclonal antibody against GD3","volume":"7","author":"Nasi","year":"1997","journal-title":"Vaccine Res."},{"issue":"5","key":"10.1016\/j.vaccine.2003.12.028_BIB2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ijc.2910350507","article-title":"Immunogenicity of melanoma-associated gangliosides in cancer patients","volume":"35","author":"Tai","year":"1985","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.vaccine.2003.12.028_BIB3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ijc.2910480312","article-title":"Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma","volume":"48","author":"Ritter","year":"1991","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.vaccine.2003.12.028_BIB4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<659::AID-IJC11>3.0.CO;2-5","article-title":"Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21","volume":"85","author":"Ragupathi","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.vaccine.2003.12.028_BIB5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1172\/JCI115276","article-title":"Induction of IgG antibodies against GD3 in rabbits by an anti-idiotypic monoclonal antibody","volume":"88","author":"Chapman","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.vaccine.2003.12.028_BIB6","first-page":"710","article-title":"Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody","volume":"4","author":"Chapman","year":"2003","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.vaccine.2003.12.028_BIB7","first-page":"679","article-title":"Enhanced immunogenicity of BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside when combined with adjuvant","volume":"2","author":"McCaffery","year":"1996","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.vaccine.2003.12.028_BIB8","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus BCG","volume":"5","author":"Grant","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vaccine.2003.12.028_BIB9","first-page":"77","article-title":"Immunization of melanoma patients with BEC2-Keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies","volume":"5","author":"Yao","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.vaccine.2003.12.028_BIB10","first-page":"874","article-title":"Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-KLH + QS21 vaccine: A dose-response study","volume":"6","author":"Chapman","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.vaccine.2003.12.028_BIB11","first-page":"4658","article-title":"Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin","volume":"6","author":"Chapman","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vaccine.2003.12.028_BIB12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI114952","article-title":"Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight melanoma-associated antigen monoclonal antibodies","volume":"86","author":"Mittelman","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.vaccine.2003.12.028_BIB13","first-page":"1","article-title":"Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer","volume":"10","author":"Kawakami","year":"1996","journal-title":"Principles Pract. Oncol."},{"issue":"1","key":"10.1016\/j.vaccine.2003.12.028_BIB14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/hyb.1997.16.23","article-title":"Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunity","volume":"16","author":"Durrant","year":"1997","journal-title":"Hybridoma"},{"key":"10.1016\/j.vaccine.2003.12.028_BIB15","first-page":"59","article-title":"Immunization of melanoma patients with anti-idiotypic monoclonal antibody BEC2 which mimics GD3 ganglioside: Pilot trials using no immunological adjuvant","volume":"3","author":"Chapman","year":"1994","journal-title":"Vaccine Res."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T21:00:20Z","timestamp":1550178020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":15,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0264410X04000775"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2003.12.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}